bemarituzumab
mAbexperimental
Bemarituzumab (INN) is a monoclonal antibody directed against fibroblast growth factor receptor 2b. It is being investigated for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma. — Wikipedia
Clinical trial activity
14 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
6
Phase 3
2
Phase 4
0
Earliest trial started Nov 1, 2014 (NCT02318329)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Endometrial Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 3
- Gastrointestinal Neoplasms · Phase 1
- Intestinal Neoplasms · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1/Phase 2
- Stomach Neoplasms · Phase 3
- Urinary Bladder Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 1/Phase 2
Mechanism of action
- Fibroblast growth factor receptor 2ANTAGONIST
Fibroblast growth factor receptor 2 antagonist
Low affinity immunoglobulin gamma Fc region receptor III-A binding agent
Binds to FCGR3A-expressing immune cells and promotes ADCC.
- Fibroblast growth factor receptor 2INHIBITOR
FGFR2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBemarituzumab ↗
- ChEMBLCHEMBL4802165 ↗
Also known as
- fpa144
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06978062 | Phase 1 | Feb 20, 2026 | European Organisation for Research and Treatment of Cancer, Johannes Gutenburg University, University of Mannheim, University of Oxford |
| NCT06967987 | Phase 2 | Dec 30, 2025 | Institut de Cancerologie de l'Ouest Paul Papin |
| NCT07146919 | Phase 1/Phase 2 (Phase 2) | Oct 15, 2025 | Centre Leon Berard |
| NCT06680622 | Phase 2 | Dec 31, 2024 | Amgen, IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Institut für Klinische Krebsforschung IKF GmbH, Johannes Gutenburg University, Technical University of Munich |
| NCT05325866 | Phase 1 | Sep 23, 2022 | Amgen |
| NCT05322577 | Phase 1/Phase 2 (Phase 2) | May 17, 2022 | Amgen |
| NCT05267470 | Phase 1 | Mar 29, 2022 | Amgen |
| NCT05052801 | Phase 3 | Dec 4, 2021 | Amgen |
| NCT05111626 | Phase 1 | Dec 1, 2021 | Amgen |
| NCT03694522 | Phase 3 | Sep 14, 2018 | Five Prime Therapeutics, Zai Lab Pty. Ltd. |
| NCT03343301 | Phase 1 | Nov 30, 2017 | Five Prime Therapeutics |
| NCT05913115 | Phase 1 | Jun 12, 2017 | Amgen |
| NCT02318329 | Phase 1 | Nov 1, 2014 | Five Prime Therapeutics |
| NCT03801278 | N/A | — | Five Prime Therapeutics |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 7 | 6 | 3 | 2017 |
| Five Prime Therapeutics | For profit | 4 | 4 | 3 | 2014 |
| Johannes Gutenburg University | Academic/Hospital | 2 | 0 | 2 | 2024 |
| Centre Leon Berard | Academic/Hospital | 1 | 1 | 1 | 2025 |
| European Organisation for Research and Treatment of Cancer | Academic/Hospital | 1 | 1 | 1 | 2026 |
| IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Institut de Cancerologie de l'Ouest Paul Papin | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Institut für Klinische Krebsforschung IKF GmbH | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Technical University of Munich | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Mannheim | Academic/Hospital | 1 | 0 | 1 | 2026 |
| University of Oxford | Academic/Hospital | 1 | 0 | 1 | 2026 |
| Zai Lab Pty. Ltd. | For profit | 1 | 0 | 1 | 2018 |
12 organizations
Page 1 / 1